Mustang Bio Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $51.09 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Mustang Bio Inc had its IPO on 2017-08-22 under the ticker symbol MBIO.
The company operates in the Healthcare sector and Biotechnology industry. Mustang Bio Inc has a staff strength of 113 employees.
Shares of Mustang Bio Inc opened at $6.29 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $5.51 - $6.29, and closed at $5.55.
This is a -11.34% slip from the previous day's closing price.
A total volume of 54,441 shares were traded at the close of the day’s session.
In the last one week, shares of Mustang Bio Inc have increased by +13.73%.
Mustang Bio Inc's Key Ratios
Mustang Bio Inc has a market cap of $51.09 million, indicating a price to book ratio of 0.6918 and a price to sales ratio of 0.
In the last 12-months Mustang Bio Inc’s revenue was $-50000 with a gross profit of $0 and an EBITDA of $-73436000. The EBITDA ratio measures Mustang Bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Mustang Bio Inc’s operating margin was 0% while its return on assets stood at -43.75% with a return of equity of -97.72%.
In Q1, Mustang Bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Mustang Bio Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-10.96 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Mustang Bio Inc’s profitability.
Mustang Bio Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.214. Its price to sales ratio in the trailing 12-months stood at 0.
Mustang Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $73.61 million
- Total Liabilities
- $12.67 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Mustang Bio Inc ended 2023 with $73.61 million in total assets and $0 in total liabilities. Its intangible assets were valued at $73.61 million while shareholder equity stood at $29.82 million.
Mustang Bio Inc ended 2023 with $0 in deferred long-term liabilities, $12.67 million in other current liabilities, 1000.00 in common stock, $-346062000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $58.10 million and cash and short-term investments were $58.10 million. The company’s total short-term debt was $629,000 while long-term debt stood at $27.58 million.
Mustang Bio Inc’s total current assets stands at $61.13 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $7.00 million and inventory worth $0.
In 2023, Mustang Bio Inc's operating cash flow was $18000.00 while its capital expenditure stood at $18000.
Comparatively, Mustang Bio Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Mustang Bio Inc stock is currently trading at $5.55 per share. It touched a 52-week high of $14.1 and a 52-week low of $14.1. Analysts tracking the stock have a 12-month average target price of $40.75.
Its 50-day moving average was $4.45 and 200-day moving average was $7.02 The short ratio stood at 1.56 indicating a short percent outstanding of 0%.
Around 2131.6% of the company’s stock are held by insiders while 1123.3% are held by institutions.
Frequently Asked Questions About Mustang Bio Inc
Similar Industry Stocks (Biotechnology)
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children’s Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.